Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-thymocyte globulin (Thymoglobulin Thymo) in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Bone Marrow Transplant
Main Authors: Al-Kadhimi, Z, Gul, Z, Abidi, M, Lum, LG, Deol, A, Chen, W, Jang, H, Ozust, C, Langston, A, Waller, E, Uberti, J
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857176/
https://ncbi.nlm.nih.gov/pubmed/28581472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2017.95
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados